539730

Fredun Pharma share price & financials

Price
₹970
Market cap
₹2.4k Cr
Sector
Healthcare
Calls analysed
5
Latest concall · Q1 FY27 · call held 13 Aug 2026

Fredun Pharma Q1 FY27

EBITDA ₹32.78 cr +93%EBITDA Margin 14.36% Net Profit ₹13.17 cr +95%Total Income ₹228.25 cr +90%

What went well

  • Stand-alone total income grew 90.44% YoY to INR228.25 crores.
  • EBITDA grew 92.90% YoY to INR32.78 crores, with margin expanding 18 bps to 14.36%.
  • Net profit grew 94.63% YoY to INR13.17 crores, with margin expanding 12 bps to 5.77%.

What to watch

  • Management was evasive about providing a specific EBIT margin target for the next 15-18 months, only stating it would be 'near that number' within 12 quarters.
  • Management declined to comment on the INR1,000 crore revenue target for FY27, stating their internal target is INR800 crores.
Read the full call →

What Fredun Pharma does

Fredun Pharmaceuticals manufactures pharmaceutical formulations at its Palghar (Maharashtra) facility, selling branded and export generics such as anti-diabetics, anti-infectives and cardiac ranges to leading Indian pharma companies and to customers across Africa, South-East Asia, CIS, Latin America and the MENA region. It also runs newer 'new-age' consumer-facing divisions - Freossi (pet healthcare and diagnostics), Fredun Nutrition (nutraceuticals), Bird n Beauty/BeautyFred (cosmeceuticals) and Fredun Mobility/Chuu Balm (orthopaedic support and pain-relief products) - largely leveraging its existing pharma distribution network. The company also does contract manufacturing for third parties at facilities beyond its own plant.

Segments

  • Generics (Exports & Fredun Gx)
  • Pet Care (Freossi)
  • Nutraceuticals (Fredun Nutrition)
  • Cosmeceuticals/Dermaceuticals (Bird n Beauty, BeautyFred)
  • Mobility (Fredun Mobility, Chuu Balm)
Registered products (global export basket)
697
Products under registration globally
1,200+
Countries with product presence/registrations
52
Certificates of Pharmaceutical Products (COPP)
400+
Contract manufacturing locations (additional to own plant)
37
Own manufacturing plant location
Palghar, Maharashtra
Founded 1987Headquarters Mumbai, Maharashtra (Registered office: Urmi Estate, Lower Parel; manufacturing plant at Palghar, Maharashtra) Company website

Guidance record · Q1 FY27

what the last two calls moved 22 tracked 1 delivered 3 missed 18 open
  • Finance Cost delivered said Q3 FY26 Promised: Decline over the next 2 to 3 quarters Q1 FY27: Management confirmed that interest costs are 'slowly reducing' due to improved cash flows and a credit rating upgrade to BBB+, fulfilling the promise made in Q3 FY26.
  • Fredun Gx Revenue missed said Q1 FY26 Promised: INR 85 crores this year (FY26) Q1 FY27: Promise related to FY26 performance, which was missed. No new update.
  • Total Revenue revised up said Q1 FY26 Promised: Double revenue to INR 800+ crores in next 3-4 years Q1 FY27: Management now expects to cross INR 800 cr in FY27, significantly accelerating the original 3-4 year timeline.

All 22 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 90.0%, net profit up 85.7% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue107 103 167 120 145 +36%161 +56%213 +28%228 +90%
EBITDA14 13 17 17 22 +57%26 +100%29 +71%33 +94%
Net profit4 5 7 7 10 +150%10 +100%11 +57%13 +86%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +13.0% 1Y

₹1.0k₹1.5k₹2.0k₹2.5kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 11 Nov 2025Q3 FY26 — 12 Feb 2026Q4 FY26 — 10 Jun 2026Q1 FY27 — 13 Aug 2026

1Y: ₹1,251.7 on 10 Sept 2025 → ₹1,414.1. High ₹2,814.3 (30 Jun 2026), low ₹885.75 (22 Jul 2026).

How the price took the results

close before → close after

Q1 FY27
+7.5%
13 Aug
Q4 FY26
+0.5%
10 Jun
Q3 FY26
−3.0%
12 Feb
Q2 FY26
+5.0%
11 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 32.2% a year over 3 years, FY23 to FY26. Operating margin widened to 14.7%.

Year endingFY23FY24FY25FY26
Revenue₹277 Cr₹349 Cr₹456 Cr₹639 Cr
Operating profit₹30 Cr₹40 Cr₹54 Cr₹94 Cr
Operating margin10.7%11.5%11.8%14.7%
Interest₹10 Cr₹14 Cr₹22 Cr₹40 Cr
Depreciation₹3 Cr₹4 Cr₹4 Cr₹8 Cr
Net profit₹11 Cr₹15 Cr₹20 Cr₹38 Cr
Net margin4.0%4.3%4.4%5.9%
Cash from operations₹-14 Cr₹0 Cr₹-21 Cr₹16 Cr
Free cash flow₹-24 Cr₹-8 Cr₹-27 Cr₹-57 Cr
ROCE18.0%17.0%19.0%21.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹4 Cr₹4 Cr₹5 Cr₹5 Cr₹5 Cr₹5 Cr
Reserves₹39 Cr₹64 Cr₹92 Cr₹117 Cr₹153 Cr₹273 Cr
Borrowings₹40 Cr₹53 Cr₹87 Cr₹106 Cr₹171 Cr₹222 Cr
Other liabilities₹79 Cr₹66 Cr₹74 Cr₹81 Cr₹136 Cr₹141 Cr
Total liabilities₹162 Cr₹187 Cr₹257 Cr₹308 Cr₹464 Cr₹642 Cr
Fixed assets₹30 Cr₹32 Cr₹39 Cr₹47 Cr₹65 Cr₹118 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹1 Cr₹2 Cr₹2 Cr
Other assets₹131 Cr₹155 Cr₹218 Cr₹260 Cr₹397 Cr₹522 Cr
Total assets₹162 Cr₹187 Cr₹257 Cr₹308 Cr₹464 Cr₹642 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jul 2026

Since Jun 2025, promoters trimmed −4.36 pp while the public added +1.94 pp. The shareholder count grew 21% to 9,598.

Promoters
44.6%
FIIs
1.1%
DIIs
2.9%
Public
51.4%

Since Jun 2025

  • Promoters −4.36 pp
  • Public +1.94 pp
  • DIIs +1.35 pp

How it drifted, 12 quarters

Over this window promoters fell from 49.2% to 44.6% — −4.6 pp.

Dec '23Mar '25Jul '26

Ownership split by quarter, oldest first. Dec '23: Promoters 49.2%, DIIs 1.6%, Public 49.2%.Mar '24: Promoters 49.2%, DIIs 1.6%, Public 49.2%.Jun '24: Promoters 49.2%, DIIs 1.6%, Public 49.2%.Sep '24: Promoters 48.9%, DIIs 1.6%, Public 49.5%.Dec '24: Promoters 48.9%, DIIs 1.6%, Public 49.5%.Mar '25: Promoters 48.9%, DIIs 1.6%, Public 49.5%.Jun '25: Promoters 48.9%, DIIs 1.6%, Public 49.5%.Sep '25: Promoters 48.9%, FIIs 0.0%, DIIs 1.6%, Public 49.5%.Dec '25: Promoters 43.1%, FIIs 0.5%, DIIs 3.5%, Public 53.0%.Mar '26: Promoters 44.2%, FIIs 1.1%, DIIs 2.8%, Public 51.9%.Jun '26: Promoters 44.6%, FIIs 1.1%, DIIs 2.9%, Public 51.5%.Jul '26: Promoters 44.6%, FIIs 1.1%, DIIs 2.9%, Public 51.4%.

Who was buying across the market this quarter →

Who bought this quarter

since Jun 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.

Who is on the register

Named in the Jul 2026 filing

Every holder of Fredun Pharma above SEBI's 1% disclosure line, and what changed since Jun 2026.

HolderStakeChange
Daulat Nariman Medhora 39.37%unchanged
Nikhil Kishorchandra Vora 5.43%newly disclosed
Fredun Nariman Medhora 5.19%unchanged
Capri Global Ventures Private Limited 1.45%newly disclosed
Bank of India Bank1.36%unchanged
Arun Kumar Mukherjee 1.24%newly disclosed
NAV Capital Vcc - NAV Capital Emerging Star Fund FPI fund1.02%unchanged
Nariman Bamansha Medhora 0.01%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

What the price assumes

Attractive

To justify its price of ₹1414, this stock must grow earnings at 8% every year for 7 years. Our analysis caps realistic growth at ~51%. At that growth it is worth ₹11558 — upside of 717%.

Growth the price implies
7.9% a year
for 7 years, fading to 4%
It has actually compounded at
50.8% a year
net profit, FY23–FY26
The gap
-0.4 pp
717% downside if it only repeats history
Price today ₹1,414.1 Value at the reference growth ₹11,558.2

Change the assumptions yourself →

All earnings calls (5)

Read the Q1 FY27 call →

Learn to analyse Fredun Pharma

Guides on how to read this kind of business and the numbers that matter.